Chronic obstructive pulmonary disease (COPD) is a commonly diagnosed condition in people older than 50 years of age. In advanced stage of this disease, integrated care (IC) is recommended as an optimal approach. IC allows for holistic and patient-focused care carried out at the patient's home. The aim of this study was to analyze the impact of IC on costs of care and on demand for medical services among patients included in IC.
Background COPD from pharmacoeconomic perspective
Chronic obstructive pulmonary disease (COPD) is a common chronic condition in people over the age of 50 years. Rapid population aging in developed countries is considered to be the main reason for higher prevalence of chronic diseases, including COPD. These changes will require some specific actions undertaken by health system decision-makers [1] .
According to WHO estimates, there are more than 65 million people worldwide suffering from COPD. This is also an important health problem in Poland. It is estimated that 10.1-10.2% of Poles have COPD [2, 3] . This is equivalent to approximately 2 million people, out of whom, 20% have an advanced stage of the disease (stage III and IV according to GOLD classification of obturation) [4] .
COPD imposes a heavy economic burden on health systems. Expenditures are approximately EUR 38.6 billion a year, of which 40-75% is spent on treatment of exacerbations requiring hospitalization [5] [6] [7] [8] [9] . Therefore, preventing exacerbations is the biggest medical and economic challenge. Similarly, in Poland, unstable disease with frequent exacerbations is related to expenditures higher by PLN 1600/year (»EUR 366.60) than in patients with stable disease [10] . In-hospital treatment of an exacerbation is up to 10 times more expensive than outpatient treatment [11] .
Thus, to achieve more effective management of the disease, particularly in advanced COPD, an innovative type of care was proposed. The Integrated Care Model (ICM) is an intervention developed in Gdansk (Pomeranian Province, Poland). The main goal of ICM was to decrease the number of exacerbations and stabilize patient condition, thereby limiting National Health Fund (NHF) expenditures.
The intervention -Integrated Care Model (ICM)
ICM includes general and specialist care combined with home support for patients, and intensive education of patients and their relatives.
All actions are synchronized by the program coordinator, who is also responsible for supervising the proper use of drugs by the patients and coordinating their visits to GPs and pulmonologists ( Figure 1 ).
As shown in Figure 1 , the coordinator is responsible for providing ongoing support to the patients. This is a non-medical staff member who has completed a specialist course in a coordination of treatment of chronically ill patients, organized by a hospice foundation, who has participated in educational training on COPD, according to the educational program developed by one of the present co-authors -Iwona DampsKonstanska, MD, PhD.
The coordinator provides patient support by: -preparing the schedule of medical and non-medical activities for ICM patients; -communicating with all ICM members; -contacting patients by phone once every 2 weeks to assess their general health condition, if they are medication-compliant, and if they require attention of medical or non-medical staff; -coordinating education of patients and their families by organizing trainings. [30] . 
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Within ICM there are 2 multidisciplinary teams working in close collaboration to assure optimal patient-oriented care.
1. The ICM medical team consists of: -pulmonologists; -medical doctors in other specializations, such as endocrinologists, cardiologists, or gastroenterologists (but only within standard care cooperation); -GPs; -nurses.
2. The ICM non-medical team consists of: -patient assistants; -dietitians; -psychologists; -physiotherapists; -social workers; -priests.
All team members are cooperating not only with each other but also with patients and their relatives. The innovative element is to integrate the activities of medical specialists and non-medical staff and to provide home support for patients with poor self-management and problems with compliance with medical recommendations.
Aim
The aim of this study was to estimate COPD costs and to analyze the impact of introducing integrated care (IC) on the public budget.
Secondary endpoints included the evaluation of: -direct medical costs for patients included and not included in ICM; -changes in costs before and after including patients in ICM; -changes in the frequency of using specific types of medical services.
Material and Methods

Study population
The study included 175 patients diagnosed with advanced COPD. The mean age of the study group was 71 years old (46-88 years) and 65% were men. The baseline characteristics are presented in Table 1 .
Cost analysis
This was a "before-after" study. The first period, called "intro6m" (meaning 6 months before introducing ICM), included 6 months of standard treatment received by all the patients. After 6 months, the study group was divided into 2 subgroups: -subgroup 1 called "ICM-no" continued standard type of care (n=131); -subgroup 2 called "ICM-yes" received integrated care (n=44).
The observation lasted for another 6 months after dividing patients into subgroups (the period called "intro+6m"). Based on prior studies on IC, the study included patients who fulfilled the specified criteria ( Figure 2 ).
Finally, the cost analysis included 154 patients. The dropouts from the study were a result of: death during the observation period (n=16), lack of COPD-related costs (n=2), and exacerbation costs (n=87). The cost analysis was divided into 3 stages. The types of costs analyzed in the study are presented in Table 2 .
Selection of DRG (Diagnosis-Related Groups) codes to describe the list of services included in the particular stages of the analysis was done on the basis of the clinical expertise of the 2 authors independently. The cost data were provided by the NHF and covered the time period from September 2012 to the end of June 2014.
The analysis included the following steps: 1. Calculating costs of standard care for all the patients included in the study; 2. Calculating costs of IC for patients fulfilling the specified criteria ( Figure 2) ; 
Results
First, the standard care costs for 6 months were evaluated for all the patients included in the cost analysis (n=154). The average half-year cost was PLN 3870.26 (»EUR 886.78), whereas the maximal cost exceeded PLN 4500 (» EUR 10310.69) ( Table 3 ).
The next step was to assess the changes in values of 3 costs types after implementation of ICM to the group of patients who fulfilled the criteria and were included in ICM. The summary data on cost changes is presented in Table 4 .
General costs
General costs were analyzed in 2 consecutive periods: before and after including patients into ICM. We found that general 
Enetering ICM at least 6 months prior to the analysis
Stage III or IV according to GOLD and PSLD criteria ICis dedicated to patients with severe condition [13] Time horizon of cost analysis differs in previous studies (3-24 months) 12 months is the commonly accepted accounting period as time of analysis, like in Kruis
At least 3 exacerbations in past year out of which at least one required hospitalization Common inclusion criterion like in [14, 15] Proper informing about the course of ICM was to ensure patients' cooperation 2853 However, the Wilcoxon's signed-rank test showed no statistical significance of the differences in the distribution of parameters (p=0.079114).
COPD costs
The costs related to COPD and other respiratory system diseases decreased significantly (Wilcoxon's Matched-Pairs SignedRank p=0.012492). Both average and median values were reduced to PLN 1450.12 (»EUR 332.26) and PLN 2010.60 (»EUR 460.68), respectively, after 6 months of ICM.
Exacerbation costs
The last stage of cost analysis was to assess exacerbation-related costs. These costs also decreased significantly (Wilcoxon's matched-pairs signed-rank p=0.017023 Changes in the number of medical procedures provided for patients After including patients in ICM, the number of medical procedures used in treating their health condition changed. There was a decrease in the number of medical services provided in most of the cases, except from gastrointestinal diseases (Figure 3) .
A similar comparison was done for the type of medical services provider. The number of services provided by GPs increased along with a decrease in the number of hospitalizations and services provided by emergency departments and paramedic teams (Figure 4 ).
Discussion
According to numerous studies, IC is a relevant and essential medical technology in the management of advanced COPD [12] [13] [14] . At the present time, it seems reasonable to determine the economic effectiveness of this technology with the use of pharmacoeconomic tools. In Poland, the role of pharmacoeconomic analyses is systematically growing and they are currently used for assessing all new and expensive procedures. They are particularly important in selecting optimal medical technologies for managing chronic diseases, including COPD, as these conditions are related to particularly high costs [11] [12] [13] [14] [15] [16] [17] .
Back in 2007, in Poland, it was found that the average direct medical costs of COPD were PLN 4027 per 1 year (»EUR 922.69) [10] . In the present study, after 8 years, the average costs were PLN 3191.43 per 6 months (»EUR 731.24) when standard care was used. Nevertheless, in our study, we decided to analyze not only COPD-related costs, but also costs of all procedures provided for patients, as it has already been proven that assessing only COPD costs is not sufficient for the meticulous calculation of actual economic burden, mainly due to the presence of multiple co-morbidities [10, 18, 19] .
Furthermore, earlier studies showed that severity of COPD is related to cost of care [8] , especially costs due to frequent hospitalizations [20] . This is one reason why ICM should be indicated for patients with advanced COPD with severe and very severe obstruction of the airways.
The cost analysis proved that patients fulfilling the criteria for participation in ICM were in a worse health status, which was confirmed by higher costs of care in the primary assessment. By comparing costs calculated for all patients (n=154) and for the ICM-yes group in the period before introducing ICM, we noticed that the costs were lower: 31% lower for general costs, 49% lower for COPD costs, and 36% lower for exacerbation costs. This confirms that the correct inclusion criteria were planned for the study, as the intention of the authors was to make ICM available for the patients in more severe condition. in Gdansk is well adjusted to the needs of COPD patients and might be an important tool for managing COPD and limiting health system expenditures. ICM is a complex intervention that includes medical and non-medical staff support provided at patients' homes, cooperation of specialist care with GPs, and supervision of adherence to medical recommendations (for a comparison of elements available for patients, see Table 5 ). A similar observation concerning the positive impact of integrated care on costs was found in 2014 by van Boven et al. [22] , who reported savings of EUR 227 per patient.
It is worth noting, though, that no statistically significant changes were found in general costs. However, after entering ICM, patients visited specialists such as dermatologists or dentists more often, which influenced the general costs. We perceive this phenomenon as positive, and it might indicate that health status improved and patients were able to use medical services that were out of reach for them before entering ICM because of poor health.
The statistically significant decrease in the COPD costs indicates that fewer procedures were provided after including patients in ICM. We believe that many health needs were satisfied by ICM and no additional procedures were necessary. Therefore, ICM seems to be appropriate for patients with advanced COPD.
Numerous have studies concentrated on the significance of preventing exacerbations that require hospitalizations [23] . This is particularly important because an exacerbation requiring hospitalization usually results in significant deterioration in health status [6] .
The decrease noticed in the exacerbation-related costs may also be considered as a decreasing number of exacerbations. Before ICM was implemented, approximately 47.7% of patients required medical services typical for exacerbations (Table 3 ). In the group of patients meeting the criteria of inclusion to ICM, the prevalence was even higher; exacerbation-related procedures were provided for 73% of patients. After 6 month of ICM in the group "ICM-yes" only 31% of patients required procedures provided for exacerbations. A similar observation was recently made by Titova et al., who noticed a difference in the number of hospitalizations between patients receiving IC and those receiving regular care (12.6% reduction in the first year and 46.5% reduction during the second year of follow-up, in comparison to 8.3% increase in the first year and no change during the second year of follow-up) [24] .
These results seem to be encouraging. Furthermore, it is worth noting that ICM seems to be more effective than many IC models described by other authors [22, 25] . For example, in a recent study by Hernandez et al., there was no reduction in the number of hospital admission found in IC in comparison with SC for stable patients [26] . Some authors found no economic efficacy of integrated care [27] . In a recently published cluster study on cost-effectiveness of IC in COPD, no economic benefit was found [28] . Table 5 shows differences and similarities between studies dealing with IC in COPD.
As contemporary knowledge of the economic effectiveness of integrated care is still not clear, the present study, conducted in Gdansk, proves ICM is an effective tool. We hope our results will be important in the worldwide discussion regarding designing effective models of care for patients and the healthcare system finances.
Conclusions
We found that ICM is a beneficial intervention for patients and the public payer. After including patients in ICM, their demand for medical services changed. The patients were rarely hospitalized and used services provided by outpatient clinics more often. Fewer procedures were continued in treating respiratory system disorders, which might indicate an improvement in the health of ICM patients.
The costs of care provided for advanced COPD patients are high, which indicates a need to evaluate traditionally used medical services and to looking for more effective ones, both from the medical and economic point of view. It seems that ICM meets these criteria, as medical costs of all analyzed types decreased when standard care was replaced by IC. Statistically significant changes were observed in costs related to COPD and exacerbations.
The obtained results show that ICM can be an effective tool to manage advanced COPD, because it reduces the number of exacerbations and therefore limits public expenditures.
Implications
This article is particularly relevant in countries where integrated care is still being implemented [29] . For specialists already using integrated care, this study confirms that IC can benefit COPD patients and the healthcare system. In countries that are still adjusting their health system to current and future challenges (e.g., demographic changes), the results obtained in Gdansk can be a guide to choosing a beneficial model of care.
After an analysis of the literature on IC, it is clear that scientific discussion on the effectiveness of this type of care is still open.
Limitations
This study has some limitations. The number of patients included in ICM was small because ICM still has no stable source 2858 of financing and is not financed from the budget of the NHF. Another limitation was using the public payer perspective in the cost analysis instead of the societal one, which is considered to be the most extensive and complete. In Poland, conducting cost analysis from the societal perspective is very difficult due to a limited access to data that is highly dispersed and collected on a fragmentary basis by various institutions. Due to using the public payer perspective, it was impossible to assess indirect costs. 
